Literature DB >> 10730196

Cisplatin.

E E Trimmer1, J M Essigmann.   

Abstract

Cisplatin is a widely used anti-cancer drug that is exceptionally effective against testicular cancer. trans-DDP, the geometric isomer of cisplatin, is ineffective as a chemotherapeutic agent. The anti-tumour activity of cisplatin is generally attributed to its formation of DNA adducts, both intrastrand and interstrand crosslinks, which induce structural distortions in DNA. The DNA adducts of cisplatin are thought to mediate its cytotoxic effects by inhibiting DNA replication and transcription and, ultimately, by inducing programmed cell death, or apoptosis. The adducts of both cis- and trans-DDP are removed from DNA by the nucleotide-excision-repair pathway. Cellular proteins possessing certain DNA-binding motifs, including the HMG domain, bind selectively to DNA modified by cisplatin, but not to DNA adducts of trans-DDP; evidence suggests a possible role for these proteins in modulating cisplatin cytotoxicity. Both intrinsic and drug-induced resistance often limit the success of cisplatin; several specific mechanisms of cisplatin resistance have been identified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10730196     DOI: 10.1042/bse0340191

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  21 in total

1.  Substrate specificity and sequence-dependent activity of the Saccharomyces cerevisiae 3-methyladenine DNA glycosylase (Mag).

Authors:  Gondichatnahalli M Lingaraju; Maria Kartalou; Lisiane B Meira; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2008-05-12

2.  p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.

Authors:  Mysore S Veena; Reason Wilken; Jun-Ying Zheng; Ankur Gholkar; Natarajan Venkatesan; Darshni Vira; Sameer Ahmed; Saroj K Basak; Clifton L Dalgard; Sandhiya Ravichandran; Raj K Batra; Noriyuki Kasahara; David Elashoff; Michael C Fishbein; Julian P Whitelegge; Jorge Z Torres; Marilene B Wang; Eri S Srivatsan
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

3.  Recombinant human erythropoietin counteracts cisplatin-induced visceral hyperalgesia.

Authors:  Min-Suk Yoon; Lars Bechmann; Mark Obermann; Olivia Yepnjouo; Rupert Egensperger; Guido Gerken; Zaza Katsarava; Juergen Thomale; Gerald Holtmann
Journal:  Neurosci Bull       Date:  2010-08       Impact factor: 5.203

Review 4.  Neurotoxic mechanisms of DNA damage: focus on transcriptional inhibition.

Authors:  Michal Hetman; Aruna Vashishta; Grzegorz Rempala
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

5.  Cisplatin abrogates the geldanamycin-induced heat shock response.

Authors:  Andrea K McCollum; Kara B Lukasiewicz; Cynthia J Teneyck; Wilma L Lingle; David O Toft; Charles Erlichman
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

6.  Ovarian cancer and DNA repair: DNA ligase IV as a potential key.

Authors:  Joana Assis; Deolinda Pereira; Rui Medeiros
Journal:  World J Clin Oncol       Date:  2013-02-10

7.  Acetylation of Werner syndrome protein (WRN): relationships with DNA damage, DNA replication and DNA metabolic activities.

Authors:  Enerlyn Lozada; Jingjie Yi; Jianyuan Luo; David K Orren
Journal:  Biogerontology       Date:  2014-06-26       Impact factor: 4.277

8.  Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.

Authors:  Carmen M Klass; Mi Sun Choe; Selwyn J Hurwitz; Mourad Tighiouart; Xin Zhang; Zhuo Georgia Chen; Dong M Shin
Journal:  Head Neck       Date:  2009-10       Impact factor: 3.147

9.  Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Authors:  Angela J Mantha; Kathryn E McFee; Nima Niknejad; Glenwood Goss; Ian A Lorimer; Jim Dimitroulakos
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-26       Impact factor: 4.553

10.  Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.

Authors:  Sumitra Mukhopadhyay; Carmen M Barnés; Ariel Haskel; Sarah M Short; Katie R Barnes; Stephen J Lippard
Journal:  Bioconjug Chem       Date:  2007-09-11       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.